1Y Close · As of Aug 26, 2026
L&K BIOMED operates in the Medical, Precision & Optical sector.
Legal name: L&K BIOMED CO., LTD.
In fiscal year 2025, L&K BIOMED (156100) reported revenue of 38.9 billion KRW, up 7.8% from 36.1 billion KRW a year earlier.
Operating profit was 715 million KRW and net income was -16.8 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 94.9 billion KRW, with a P/B of 2.46.
These figures can be verified in the DART filing (receipt no. 20260312001180).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 38.9B | 715M | -16.8B |
| 2024 | 36.1B | 3.1B | 9.2B |
| 2023 | 29.9B | 2.0B | -5.2B |
Recent Filings
Guarantee Decision
Officer/Major Shareholder Ownership Report
Conversion Price Adjustment
Checks
1 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Administrative Designation: No administrative designation criteria met.
Audit Opinion: Audit opinion: Unqualified (clean).
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-24 | Guarantee Decision |
| 2026-08-20 | Officer/Major Shareholder Ownership Report |
| 2026-08-19 | Conversion Price Adjustment |
| 2026-08-14 | Semi-Annual Report (2026.06) |
| 2026-08-11 | Large Shareholding Report (General) |